



Alliance Neurooncology Committee Agenda

Saturday, May 10, 2014

Open Session: 9:30 am – 12:30 pm

InterContinental Chicago O'Hare

Alliance NeuroOnc Committee Call-in Information

Teleconference #: 1-800-501-8979

Access Code: 3057352

Welcome – Overview

E. Galanis

Active Protocols and Concepts in Development

Newly Diagnosed GBM

N0874 Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA])Temozolomide, and Radiation Therapy in Patients with Newly Diagnosed Glioblastoma (Completed)

E. Galanis/P. Wen

N0877 Phase I Randomized Phase II Trial of Either Dasatanib or Placebo Combined with Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM) (Accrual goal met on 12/6/13)

E. Galanis

Phase I/II Study of MK-1175 with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma

B. Alexander

A071102: Randomized Trial of ABT-888 or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed GBM with MGMT Promoter Hypermethylation

J. Sarkaria

Individualized Screening trial of Innovative Glioblastoma Therapy (INSIGHt)

B. Alexander

Recurrent GBM

N0872 Phase I Randomized Phase II Double Blinded Study of Either Dasatanib or Placebo Combined with Bevacizumab in Recurrent Glioblastoma (Accrual goal met on 3/27/14)

E. Galanis

A071101: A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPCC-96) NSC #725085, BB IND# Pending) Vaccine Given with Bevacizumab versus Bevacizumab alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)

A. Parsa

A071201: Phase I/Randomized Comparative Phase II Trial of TRC105 plus Bevacizumab versus Bevacizumab in Bevacizumab-Naïve Patients with Recurrent Glioblastoma Multiforme

E. Galanis/P. Wen

Phase II trial of the Aurora A Kinase Inhibitor MLN8237 in Recurrent Glioblastoma B. Friday

Anaplastic Gliomas – Newly Diagnosed

N0577 Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma K. Jaeckle/E. Galanis

EORTC 26053-22054 Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma: The CATNON Intergroup Trial K. Jaeckle/E. Galanis

Low Grade Gliomas

E3F05 Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas P. Brown

R0925: Natural History in Low Risk LGG P. Brown

Meningiomas

Phase II Trial of SMO/AKT Inhibitors in Progressive Meningiomas with SMO/AKT Mutations P. Brastianos

Brain Metastases

N0574 A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) (Accrual goal met on 11/8/13) P. Brown

N017C A Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy In Addition to Radiosurgery in the Management of Patients with One to Three Cerebral Metastases P. Brown

Symptom Control

A221101: A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with Glioblastoma Multiforme A. Porter

A221208: Bevacizumab vs. Steroids (BeSt) for Radionecrosis after Radiosurgery: A Randomized Phase II Trial C. Chung